Bookmark
Forward
Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.
Cancer discovery 2020 AprSizes of these terms reflect their relevance to your search.
The anti-HER2-drug conjugate trastuzumab deruxtecan (T-DXd) was effective in HER2-low breast cancer. ©2020 American Association for Cancer Research.
Citation
Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer. Cancer discovery. 2020 Apr;10(4):488
Mesh Tags
Substances
PMID: 32111601
View Full Text
